A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Status:
Recruiting
Trial end date:
2024-09-14
Target enrollment:
Participant gender:
Summary
The purpose of this study to find out whether mirdametinib is a safe treatment for people
with advanced solid tumor cancer that has certain mutations. Researchers will look at whether
mirdametinib on its own or in combination with the drug fulvestrant is a safe treatment that
causes few or mild side effects in people with advanced solid tumor cancer.